Cyclooxygenase-2 inhibitor

Class of drugs that selectively inhibit cyclooxygenase-2 (COX-2)

Cyclooxygenase-2 inhibitors (COX-2 inhibitors) are a class of nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the enzyme cyclooxygenase-2 (COX-2). These drugs are used primarily for their anti-inflammatory, analgesic, and antipyretic properties while aiming to reduce gastrointestinal side effects associated with traditional NSAIDs.

Mechanism of Action

COX-2 inhibitors function by selectively blocking the cyclooxygenase-2 (COX-2) enzyme, which is responsible for:

• The production of prostaglandins involved in pain and inflammation.
• Mediating fever and swelling at injury sites.
• Reducing pain perception by lowering prostaglandin levels in the nervous system.

Unlike traditional NSAIDs (e.g., ibuprofen and naproxen), COX-2 inhibitors spare cyclooxygenase-1 (COX-1), which plays a crucial role in:

• Protecting the gastric lining.
• Maintaining renal function.
• Supporting platelet aggregation.

By selectively inhibiting COX-2, these drugs aim to reduce pain and inflammation while minimizing gastric ulceration and bleeding, a common side effect of non-selective NSAIDs.

Indications

COX-2 inhibitors are prescribed for:

• Osteoarthritis – To relieve joint pain and stiffness.
• Rheumatoid arthritis – To reduce inflammation in autoimmune joint disease.
• Ankylosing spondylitis – A chronic inflammatory spinal disorder.
• Acute pain – Post-surgical pain, dental procedures, and musculoskeletal injuries.
• Dysmenorrhea – Painful menstrual cramps.
• Familial adenomatous polyposis (FAP) – Celecoxib has been studied for its role in reducing colorectal polyps.

Common COX-2 Inhibitors

List of Selective COX-2 Inhibitors

Drug Name	Brand Names	Status
Celecoxib	Celebrex	Widely used
Etoricoxib	Arcoxia	Approved in several countries, but not in the US
Parecoxib	Dynastat	Injectable COX-2 inhibitor
Rofecoxib	Vioxx	Withdrawn due to cardiovascular risks
Valdecoxib	Bextra	Withdrawn due to cardiovascular risks

Safety and Risks

Although COX-2 inhibitors offer gastrointestinal safety, they have been associated with increased risks of cardiovascular events such as:

• Heart attack (myocardial infarction).
• Stroke (ischemic stroke).
• Hypertension (high blood pressure).

These risks led to the withdrawal of rofecoxib (Vioxx) and valdecoxib (Bextra) from the market. The FDA and EMA continue to monitor the safety of celecoxib and other COX-2 inhibitors.

Comparison with Traditional NSAIDs

Comparison of COX-2 Inhibitors vs. Traditional NSAIDs

Feature	COX-2 Inhibitors	Traditional NSAIDs
Gastrointestinal Safety	Lower risk of ulcers and bleeding	Higher risk of ulcers and GI bleeding
Cardiovascular Risk	Increased risk	Variable risk
Platelet Effects	No significant inhibition of platelets	Inhibits platelet aggregation
Anti-inflammatory Action	Similar to NSAIDs	Strong anti-inflammatory effect

Contraindications

COX-2 inhibitors should be avoided in:

• Patients with a history of heart disease or stroke.
• Individuals with severe kidney disease.
• Those allergic to sulfonamides (some COX-2 inhibitors contain sulfa components).
• Pregnant women, particularly in the third trimester.

Drug Interactions

COX-2 inhibitors may interact with:

• Aspirin – May negate the gastrointestinal safety benefits.
• Warfarin and other anticoagulants – Increased risk of bleeding.
• Diuretics (e.g., furosemide, hydrochlorothiazide) – May reduce diuretic effectiveness.
• ACE inhibitors and ARBs – Can impair kidney function when used together.

Current Regulatory Status

• Rofecoxib (Vioxx) – Withdrawn worldwide in 2004 due to cardiovascular risks.
• Valdecoxib (Bextra) – Withdrawn in 2005.
• Celecoxib (Celebrex) – Still available but with cardiovascular risk warnings.
• Etoricoxib (Arcoxia) – Approved in Europe, Asia, and Latin America, but not in the United States.

Research and Future Developments

New research is focused on:

• Developing safer COX-2 inhibitors with reduced cardiovascular risks.
• Studying COX-2 inhibition in cancer therapy.
• Investigating the role of COX-2 inhibitors in Alzheimer’s disease and neurological conditions.

See Also

• Nonsteroidal anti-inflammatory drugs (NSAIDs)
• Lipid metabolism
• Prostaglandins
• Cyclooxygenase
• Analgesics